• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

年龄和淋巴细胞/单核细胞比值是预测滤泡性淋巴瘤患者自体移植治疗预后的因素。

Age and lymphocyte/monocyte ratio as prognostic factors for autologous transplantation in the treatment of patients with follicular lymphoma.

机构信息

Department of Hematology, Faculty of Medicine, Medical School of Clinical Medicine, University of Debrecen, Hungary.

Doctoral School of Clinical Medicine, University of Debrecen, Hungary.

出版信息

J Int Med Res. 2024 Feb;52(2):3000605231221012. doi: 10.1177/03000605231221012.

DOI:10.1177/03000605231221012
PMID:38321883
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10851732/
Abstract

OBJECTIVE

Follicular lymphoma (FL) is an indolent, lymphoproliferative disease of B-cell origin that has a heterogeneous disease course with varying outcomes. Certain patients may undergo autologous stem cell transplantation. We investigated the outcome of autologous stem cell transplantation in patients with FL.

METHODS

Patients who received autologous stem cell transplantation at the University of Debrecen's Department of Hematology between 2004 and 2021 were retrospectively analyzed. The overall survival (OS) and progression-free survival (PFS) after transplantation of patients with FL were examined. Prognostic factors that may influence the course of the disease were chosen.

RESULTS

Data were collected from 49 patients. OS was influenced only by age, whereas PFS was affected by age and the lymphocyte/monocyte ratio. The combination of age and lymphocyte/monocyte ratio defined a patient population with a particularly unfavorable prognostic risk profile: patients over 47 years of age with a pre-transplant lymphocyte/monocyte ratio greater than or equal to 2.675.

CONCLUSION

Age and lymphocyte/monocyte ratio were identified as useful prognostic factors for PFS in patients with FL following autologous stem cell transplantation.

摘要

目的

滤泡性淋巴瘤（FL）是一种起源于 B 细胞的惰性、淋巴增殖性疾病，其疾病过程具有异质性，结局不一。某些患者可能会接受自体干细胞移植。我们研究了 FL 患者自体干细胞移植的结果。

方法

回顾性分析了 2004 年至 2021 年在德布勒森大学血液科接受自体干细胞移植的患者。检查了 FL 患者移植后的总生存率（OS）和无进展生存率（PFS）。选择了可能影响疾病进程的预后因素。

结果

共收集了 49 名患者的数据。OS 仅受年龄影响，而 PFS 则受年龄和淋巴细胞/单核细胞比值影响。年龄和淋巴细胞/单核细胞比值的组合定义了一个具有特别不利预后风险特征的患者群体：年龄大于 47 岁且移植前淋巴细胞/单核细胞比值大于或等于 2.675。

结论

年龄和淋巴细胞/单核细胞比值是自体干细胞移植后 FL 患者 PFS 的有用预后因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c87/10851732/bddf6d1bf186/10.1177_03000605231221012-fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c87/10851732/415bb4cf6b25/10.1177_03000605231221012-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c87/10851732/b5c284f88813/10.1177_03000605231221012-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c87/10851732/74f6e4df29e5/10.1177_03000605231221012-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c87/10851732/5e523ca15ca8/10.1177_03000605231221012-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c87/10851732/38719742f959/10.1177_03000605231221012-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c87/10851732/bddf6d1bf186/10.1177_03000605231221012-fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c87/10851732/415bb4cf6b25/10.1177_03000605231221012-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c87/10851732/b5c284f88813/10.1177_03000605231221012-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c87/10851732/74f6e4df29e5/10.1177_03000605231221012-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c87/10851732/5e523ca15ca8/10.1177_03000605231221012-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c87/10851732/38719742f959/10.1177_03000605231221012-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c87/10851732/bddf6d1bf186/10.1177_03000605231221012-fig6.jpg

相似文献

1
Age and lymphocyte/monocyte ratio as prognostic factors for autologous transplantation in the treatment of patients with follicular lymphoma.年龄和淋巴细胞/单核细胞比值是预测滤泡性淋巴瘤患者自体移植治疗预后的因素。
J Int Med Res. 2024 Feb;52(2):3000605231221012. doi: 10.1177/03000605231221012.
2
Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index.滤泡性非霍奇金淋巴瘤自体干细胞移植的长期预后：组织学分级和滤泡国际预后指数的影响
Biol Blood Marrow Transplant. 2008 Jan;14(1):36-42. doi: 10.1016/j.bbmt.2007.06.016. Epub 2007 Dec 3.
3
High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.成人滤泡性淋巴瘤采用自体干细胞移植高剂量疗法与化疗或免疫化疗的比较
Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD007678. doi: 10.1002/14651858.CD007678.pub2.
4
Can Neutrophil-to-Lymphocyte Ratio, Monocyte-to-Lymphocyte Ratio, and Platelet-to-Lymphocyte Ratio at Day +100 be used as a prognostic marker in Multiple Myeloma patients with autologous transplantation?中性粒细胞与淋巴细胞比值、单核细胞与淋巴细胞比值和血小板与淋巴细胞比值在第 +100 天能否作为自体移植多发性骨髓瘤患者的预后标志物？
Clin Transplant. 2018 Sep;32(9):e13359. doi: 10.1111/ctr.13359. Epub 2018 Aug 26.
5
Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era.利妥昔单抗时代自体造血干细胞移植后复发性滤泡性淋巴瘤的临床特征和结局。
Hematol Oncol. 2020 Apr;38(2):137-145. doi: 10.1002/hon.2713. Epub 2020 Jan 30.
6
Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response.复发或高级别滤泡性淋巴瘤患者进行自体移植可实现长期无病生存，并获得最佳的中位缓解持续时间。
Ann Hematol. 2005 Aug;84(8):526-31. doi: 10.1007/s00277-005-1058-9. Epub 2005 May 25.
7
Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.异基因造血干细胞移植治疗复发性滤泡淋巴瘤：代表 EBMT 淋巴瘤工作组和 CIBMTR 淋巴瘤委员会的联合分析。
Cancer. 2018 Apr 15;124(8):1733-1742. doi: 10.1002/cncr.31264. Epub 2018 Feb 9.
8
A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma.对复发、侵袭性、转化型和非转化型滤泡性淋巴瘤进行早期和晚期自体造血干细胞移植的15年分析。
Biol Blood Marrow Transplant. 2007 Aug;13(8):956-64. doi: 10.1016/j.bbmt.2007.04.009.
9
Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.自体与减低强度异基因造血细胞移植治疗首次完全缓解或部分缓解后化疗敏感的滤泡性非霍奇金淋巴瘤患者。
Biol Blood Marrow Transplant. 2011 Jul;17(7):1051-7. doi: 10.1016/j.bbmt.2010.11.004. Epub 2010 Nov 10.
10
Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure.自体干细胞移植治疗滤泡性淋巴瘤在疾病早期最有益，可以产生持久缓解，与先前是否使用利妥昔单抗无关。
Br J Haematol. 2014 May;165(3):334-40. doi: 10.1111/bjh.12741. Epub 2014 Jan 18.

引用本文的文献

1
Response Duration During Treatment of Patients with Follicular Lymphoma.滤泡性淋巴瘤患者治疗期间的反应持续时间。
Biomedicines. 2025 Jun 11;13(6):1433. doi: 10.3390/biomedicines13061433.
2
Prognostication of Follicular Lymphoma: A Review of Prognostic Scores and Factors.滤泡性淋巴瘤的预后评估：预后评分与因素综述
Diagnostics (Basel). 2025 Mar 6;15(5):647. doi: 10.3390/diagnostics15050647.

本文引用的文献

1
Clinical and biological prognostic factors in follicular lymphoma patients.滤泡性淋巴瘤患者的临床和生物学预后因素。
PLoS One. 2022 Aug 4;17(8):e0272787. doi: 10.1371/journal.pone.0272787. eCollection 2022.
2
Prospects in the management of patients with follicular lymphoma beyond first-line therapy.滤泡性淋巴瘤一线治疗以外患者管理的前景。
Haematologica. 2022 Jan 1;107(1):19-34. doi: 10.3324/haematol.2021.278717.
3
Long-term outcome in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation.
滤泡性淋巴瘤患者接受高剂量化疗和自体造血干细胞移植后的长期疗效。
Eur J Haematol. 2021 Nov;107(5):543-552. doi: 10.1111/ejh.13691. Epub 2021 Aug 3.
4
Cost-effectiveness analysis of allogeneic versus autologous stem cell transplant versus chemo-immunotherapy for early relapse of follicular lymphoma within 2 years of initial therapy.同种异体与自体干细胞移植与化疗免疫治疗对初始治疗 2 年内早期滤泡性淋巴瘤复发的成本效益分析。
Bone Marrow Transplant. 2021 Oct;56(10):2400-2409. doi: 10.1038/s41409-021-01327-5. Epub 2021 May 13.
5
Impact of event-free survival status after stem cell transplantation on subsequent survival of patients with lymphoma.干细胞移植后无事件生存状态对淋巴瘤患者后续生存的影响。
Blood Adv. 2021 Mar 9;5(5):1412-1424. doi: 10.1182/bloodadvances.2020003735.
6
Does Up-front Autologous Stem-Cell Transplantation at First Relapse Improve Outcome in Transplant-Eligible Follicular Lymphoma Patients Whose Disease Relapses Within 24 Months?在首次复发时进行 upfront 自体干细胞移植是否能改善在 24 个月内疾病复发的适合移植的滤泡性淋巴瘤患者的预后？
Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):e423-e427. doi: 10.1016/j.clml.2020.12.011. Epub 2021 Feb 6.
7
Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial.自体移植后利妥昔单抗维持治疗对复发性滤泡性淋巴瘤患者的持久获益：EBMT 淋巴瘤工作组 Lym1 试验 12 年随访结果。
Bone Marrow Transplant. 2021 Jun;56(6):1413-1421. doi: 10.1038/s41409-020-01182-w. Epub 2021 Jan 15.
8
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.新诊断及复发滤泡性淋巴瘤：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2021 Mar;32(3):298-308. doi: 10.1016/j.annonc.2020.11.008. Epub 2020 Nov 26.
9
Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study.自体干细胞移植治疗初治转化惰性 B 细胞淋巴瘤：一项国际多中心倾向评分匹配研究。
Br J Haematol. 2020 Dec;191(5):806-815. doi: 10.1111/bjh.17072. Epub 2020 Oct 16.
10
Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models.通过临床和遗传风险模型评估滤泡性淋巴瘤 R-CHOP 后高剂量巩固治疗。
Blood Adv. 2020 Sep 22;4(18):4451-4462. doi: 10.1182/bloodadvances.2020002546.